1 Min Read
March 21 (Reuters) - Viking Therapeutics Inc
* Viking therapeutics reports fourth quarter and year-end 2016 financial results and provides corporate update
* Q4 loss per share $0.18
* Q4 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S
* Viking therapeutics inc - at december 31, 2016, viking held cash, cash equivalents and investments totaling $13.2 million.
* Says company currently expects to complete phase 2 trial of vk2809 in late 2017 Source text for Eikon: Further company coverage: